| Literature DB >> 33703996 |
Nannan Wu1, Jia Dai1, Mingquan Guo1,2, Jianhui Li1, Xin Zhou1, Feng Li3, Yuan Gao4, Hongping Qu5, Hongzhou Lu6, Jing Jin7, Tao Li8, Lei Shi9, Qingguo Wu3, Ruoming Tan5, Mingli Zhu4, Lan Yang1, Yun Ling10, Shunpeng Xing4, Jianzhong Zhang11, Bangxin Yao11, Shuai Le1,12, Jingmin Gu1,13, Jinhong Qin1,14, Jie Li1, Mengjun Cheng1, Demeng Tan1, Linlin Li1, Yiyuan Zhang1, Zhaoqin Zhu2, Jinfeng Cai2, Zhigang Song15, Xiaokui Guo1,14, Li-Kuang Chen1,16, Tongyu Zhu1,17.
Abstract
Phage therapy is recognized as a promising alternative to antibiotics in treating pulmonary bacterial infections, however, its use has not been reported for treating secondary bacterial infections during virus pandemics such as coronavirus disease 2019 (COVID-19). We enrolled 4 patients hospitalized with critical COVID-19 and pulmonary carbapenem-resistant Acinetobacter baumannii (CRAB) infections to compassionate phage therapy (at 2 successive doses of 109 plaque-forming unit phages). All patients in our COVID-19-specific intensive care unit (ICU) with CRAB positive in bronchoalveolar lavage fluid or sputum samples were eligible for study inclusion if antibiotic treatment failed to eradicate their CRAB infections. While phage susceptibility testing revealed an identical profile of CRAB strains from these patients, treatment with a pre-optimized 2-phage cocktail was associated with reduced CRAB burdens. Our results suggest the potential of phages on rapid responses to secondary CRAB outbreak in COVID-19 patients.Entities:
Keywords: COVID-19; Phage therapy; carbapenem-resistant Acinetobacter baumannii; nosocomial infections
Mesh：
Year: 2021 PMID： 33703996 DOI： 10.1080/22221751.2021.1902754
Source DB: PubMed Journal: Emerg Microbes Infect ISSN： 2222-1751 Impact factor: 7.163